Additive Homeopathy in Cancer Patients
Malignant Tumors
Conditions: official terms
Conditions: Keywords
cancer, additive homeopathy, patients with advanced malignant tumors
Study Type
Study Phase
Phase 2/Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Name: Additive classical homeopathy Type: Drug
Name: Placebo homeopathic globules Type: Drug
Name: Placebo globules Type: Drug
Overall Status
The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patients with advanced malignant tumors. The investigators plan to compare the treatment outcome (quality of life and survival) in tumor patients, receiving standard or "add-on" homeopathic treatment.

The null hypothesis is that "add-on" homeopathic treatment does not create a benefit for cancer patients. In addition the investigators evaluate survival time.
Detailed Description
The EORTC-QLQ-C30 as well as a VAS scale for subjective well-being will be filled out by the patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Informed consent

- Clinical diagnosis of advanced tumor stages of glioblastoma IV, metastasized sarcoma, as well as non small-cell lung carcinoma (NSCLC) IV.

Exclusion Criteria:

- Pregnant patients
Medical University Vienna
Vienna, Austria
Status: Recruiting
Contact: Michael Frass, Prof. Dr. - +43 1 40400 -
Start Date
January 2011
Completion Date
January 2019
Medical University of Vienna
Medical University of Vienna
Record processing date processed this data on July 28, 2015 page